Dormant tumor cells develop cross-resistance to apoptosis induced by CTLs or imatinib mesylate via methylation of suppressor of cytokine signaling 1

Cancer Research

Volumn 67, Issue 9, 2007, Pages 4491-4498

  Saudemont, Aurore ^a,d   Hamrouni, Abdelbasset ^a   Marchetti, Philippe ^a   Liu, Jizhong ^a   Jouy, Nathalie ^b   Hetuin, Dominique ^a   Colucci, Francesco ^d   Quesnel, Bruno ^a,c  

^a Institut de Recherche sur le Cancer de Lille   (France)

^b UNIV LILLE   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d BABRAHAM INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CYTARABINE; CYTOKINE ANTIBODY; IMATINIB; INTERLEUKIN 3; INTERLEUKIN 3 ANTIBODY; JANUS KINASE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; STAT PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS RESISTANCE; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DEMETHYLATION; DNA METHYLATION; DRUG MECHANISM; ENZYME REGULATION; GENE EXPRESSION; GENE SILENCING; GENE TRANSFER; GENETIC TRANSFECTION; IMMUNE RESPONSE; IRRADIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR CELL;

ANIMALS; APOPTOSIS; DNA METHYLATION; GENE EXPRESSION REGULATION, LEUKEMIC; GENE SILENCING; JANUS KINASES; LEUKEMIA, MYELOCYTIC, ACUTE; MICE; MICE, INBRED C3H; PIPERAZINES; PROMOTER REGIONS (GENETICS); PYRIMIDINES; STAT TRANSCRIPTION FACTORS; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION;

EID: 34249275321     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1627     Document Type: Article

References (50)

1. Uhr JW, Marches R. Dormancy in a model of murine B cell lymphoma. Semin Cancer Biol 2001;11:277-83.
2. Davis TA, Maloney DG, Czerwinski DK, Liles TM, Levy R. Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. Blood 1998;92: 1184-90.
3. + cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 2005; 105:2093-8.
4. + progenitors are resistant to apoptosis induced bv a wide range of proapoptotic stimuli. Leukemia 2005;19: 1034-41.
5. Bhatia R, Holtz M, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003;101:4701-7.
6. Allard WJ, Matera J, Miller MC, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004;10:6897-904.
7. Meng S, Tripathy D, Frenkel EP, et al. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 2004;10:8152-62.
8. Vitetta FS, Tucker TF, Racila E, et al. Tumor dormancy and cell signaling. V. Regrowth of the BCL1 tumor after dormancy is established. Blood 1997;89:4425-36.
9. Saudemont A, Buffenoir G, Denys A, et al. Gene transfer of CD154 and IL12 cDNA induces an antileukemic immunity in a murine model of acute leukemia. Leukemia 2002;16:1637-44.
10. Vereecque R, Buffenoir G, Preudhomme C, et al. Gene transfer of GM-CSF, CD80 and CD154 cDNA enhances survival in a murine model of acute leukemia with persistence of a minimal residual disease. Gene Ther 2000;7:1312-6.
11. Saudemont A, Quesnel B. In a model of tumor dormancy, long-term persistent leukemic cells have increased B7-1 and B7.1 expression and resist CTL-mediated lysis. Blood 2004;104:2124-33.
12. Alexander WS, Hilton DJ. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol 2004;22:503-29.
13. Kile BT, Schulman BA, Alexander WS, Nicola NA, Martin HM, Hilton DJ. The SOCS box: a tale of destruction and degradation. Trends Biochem Sci 2002;27:235-41.
14. Rottapel R, Ilangumaran S, Neale C, et al. The tumor suppressor activity of SOCS-1. Oncogene 2002; 21:4351-62.
15. Frantsve J, Schwaller J, Sternberg DW, Kutok J, Gilliland DG. Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation. Mol Cell Biol 2001;21:3547-57.
16. Kamizono S, Hanada T, Yasukawa H, et al. The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2. J Biol Chem 2001;276:12530-8.
17. Saudemont A, Jouy N, Hetuin D, Quesnel B. NK cells that are activated by CXCL10 can kill dormant tumor cells that resist CTL-mediated lysis and can express B7-1 that stimulates T cells. Blood 2005;105:2428-35.
18. Lo YM, Wong IH, Zhang J, Tein MS, Ng MH, Hjelm NM. Quantitative analysis of aberrant p16 methylation using real-time quantitative methylation-specific polymerase chain reaction. Cancer Res 1999;59:3899-903.
19. + thymocytes. Blood 2003;102: 4115-22.
20. Marchetti P, Castedo M, Susin SA et al. Mitochondrial permeability transition is a central coordinating event of apoptosis. J Exp Med 1996;184:1155-60.
21. Zhang JG, Farley A, Nicholson SE, et al. The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc Natl Acad Sci U S A 1999;96:2071-6.
22. Mansell A, Smith R, Doyle SL, et al. Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation. Nat Immunol 2006;7:148-55.
23. Ryo A, Suizu F, Yoshida Y, et al. Regulation of NF-κB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol Cell 2003;12:1413-26.
24. Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J. Inhibition of nuclear translocation of transcription factor NF-κB by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem 1995;270:14255-8.
25. Mahnke YD, Schwendemann J, Beckhove P, Schirrmacher V. Maintenance of long-term tumour-specific T-cell memory by residual dormant tumour cells. Immunology 2005;115:325-36.
26. Schirrmacher V. T-cell immunity in the induction and maintenance of a tumour dormant state. Semin Cancer Biol 2001;11:285-95.
27. + T cells and IFN-γ in establishing and maintaining the tumor-dormant state. J Immunol 1999;162:2842-9.
28. Yefenof E, Picker LJ, Scheuermann RH, Tucker TF, Vitetta ES, Uhr JW. Cancer dormancy: isolation and characterization of dormant lymphoma cells. Proc Natl Acad Sci U S A 1993;90:1829-33.
29. + immune T cells. Cancer Res 1998;58: 5439-46.
30. Khazaie K, Prifti S, Beckhove P, et al. Persistence of dormant tumor cells in the bone marrow of tumor cell-vaccinated mice correlates with long-term immunological protection. Proc Natl Acad Sci U S A 1994;91:7430-4.
31. Schirrmacher V, Beckhove P, Choi C, Griesbach A, Mahnke Y. Tumor-immune memory T cells from the bone marrow exert GvL without GvH reactivity in advanced metastasized cancer. Int J Oncol 2005;27: 1141-9.
32. Yamshchikov GV, Mullins DW, Chang CC, et al. Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma. J Immunol 2005;174:6863-71.
33. Reddy J, Shivapurkar N, Takahashi T, et al. Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors. Oncogene 2005;24:732-6.
34. Galm O, Wilop S, Reichelt J, et al. DNA methylation changes in multiple myeloma. Leukemia 2004; 18:1687-92.
35. Yoshida T, Ogata H, Kamio M, et al. SOCS1 is a suppressor of fiver Fibrosis and hepatitis-induced carcinogenesis. J Exp Med 2004;199:1701-7.
36. Sutherland KD, Lindeman GJ, Choong DY, et al. Differential hypermethylation of SOCS genes in ovarian and breast carcinomas. Oncogene 2004;23:7726-33.
37. Galm O, Yoshikawa H, Esteller M, Osieka R, Herman JG. SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood 2003;101:2784-8.
38. Chen CY, Tsay W, Tang JL, et al. SOCS1 methylation in patients with newly diagnosed acute myeloid leukemia. Genes Chromosomes Cancer 2003;37:300-5.
39. Melzner I, Moller P. Silencing of the SOCS-1 gene by CpG methylation? Blood 2003;102:1554-5.
40. Zardo G, Tiirikainen MI, Hong C, et al. Integrated genomic and epigenomic analyses pinpoint biallelic gene inactivation in tumors. Nat Genet 2002;32:453-8.
41. Nagai H, Kim YS, Konishi N, et al. Combined hypermethylation and chromosome loss associated with inactivation of SSI-1/SOCS-1/JAB gene in human hepatocellular carcinomas. Cancer Lett 2002;186:59-65.
42. Depil S, Saudemont A, Quesnel B. SOCS-1 gene methylation is frequent but does not appear to have prognostic value in patients with multiple myeloma. Leukemia 2003;17:1678-9.
43. Johan MF, Bowen DT, Frew ME, Goodeve AC, Reilly JT. Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 2005;129:60-5.
44. Chim CS, Fung TK, Cheung WC, Liang R, Kwong YL. SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/ STAT pathway. Blood 2004;103:4630-5.
45. Miyoshi H, Fujie H, Shintani Y, et al. Hepatitis C virus core protein exerts an inhibitory effect on suppressor of cytokine signaling (SOCS)-1 gene expression. J Hepatol 2005;43:757-63.
46. Shachaf CM, Felsher DW. Tumor dormancy and MYC inactivation: pushing cancer to the brink of normalcy. Cancer Res 2005;65:4471-4.
47. Shachaf CM, Kopelman AM, Arvanitis C, et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004;431:1112-7.
48. Jiang X, Lopez A, Holyoake T, Eaves A, Eaves C. Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proc Natl Acad Sci U S A 1999;96:12804-9.
49. Wang Y, Cai D, Brendel C, et al. Adaptive secretion of the granulocyte macrophage colony stimulating factor (GM-CSF) mediates imatinib- and nilotinib-resistance in BCR/ABL-positive progenitors via JAK-2/STAT-5 pathway activation. Blood 2006. Epub ahead of print.
50. Samanta AK, Lin H, Sun T, Kantarjian H, Arlinghaus RB. Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res 2006;66:6468-72.